MAP3K20

Across TCGA pan-cancer cohorts, MAP3K20 mass-spec protein differs between tumor and matched normal tissue in 5 of 18 cancer types tested, making tumor–normal expression one of MAP3K20’s most consistent transcriptional readouts.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where MAP3K20 mass-spec protein is more highly expressed in tumor relative to normal tissue. In most cancer types MAP3K20 is over-expressed in tumor, although a few such as COAD and LUAD show the opposite, repressed pattern.

CCRCC, COAD, and LUAD are the cancer types where MAP3K20 tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in MAP3K20 mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
CCRCC	All	IV	+0.624	<.001	12	view →
COAD	Male	III,IV	−0.828	<.001	9	view →
LUAD	Female	III,IV	−0.630	<.001	9	view →
LSCC	All	All	−0.377	<.001	8	view →
OV	All	All	−1.137	<.001	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 5 strongest of 5 lineages.

MAP3K20–CCRCC

Open the CCRCC breakdown →